BGNE: BeiGene is a Sell

The current rating for BGNE is 43, which is 16% below its historic median rating of 50. This indicates higher risk than normal.

The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.